TapImmune Announces Pricing of $70 Million Private Placement

Financing Led by New Enterprise Associates (NEA) Financing to Close Concurrently with Close of Merger with Marker Therapeutics JACKSONVILLE, Florida, June 8, 2018 – TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of…

Details

TapImmune to Present at the Jefferies 2018 Global Healthcare Conference

JACKSONVILLE, Florida, May  31, 2018 – TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will present at the Jefferies 2018 Global Healthcare Conference taking place June 5-8, 2018, in New York City. TapImmune Company Presentation Date : Thursday, June 7, 2018 Time : 3:30 PM…

Details